Plasma SIRT3 as a Biomarker of Severity and Prognosis After Acute Intracerebral Hemorrhage: A Prospective Cohort Study
Tian Yan,Ze-Fan Wang,Xiao-Yu Wu,Quan Du,Wen-Hua Yu,Wei Hu,Yong-Ke Zheng,Ke-Yi Wang,Xiao-Qiao Dong
DOI: https://doi.org/10.2147/NDT.S376717
IF: 2.989
2022-09-27
Neuropsychiatric Disease and Treatment
Abstract:Tian Yan, 1 Ze-Fan Wang, 1 Xiao-Yu Wu, 1 Quan Du, 2 Wen-Hua Yu, 2 Wei Hu, 3 Yong-Ke Zheng, 3 Ke-Yi Wang, 4 Xiao-Qiao Dong 2 1 The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; 2 Department of Neurosurgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 3 Department of Intensive Care Unit, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 4 Clinical Laboratory Center, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China Correspondence: Xiao-Qiao Dong, Department of Neurosurgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China, Email Objective: SIRT3 may act as a brain-protective factor. We measured the plasma SIRT3 levels of patients with intracerebral hemorrhage (ICH) and further determined the relationship between plasma SIRT3 and clinical outcome plus severity of ICH. Methods: In this prospective cohort study, we quantified plasma SIRT3 levels in 105 ICH patients and 72 healthy controls. Glasgow Coma Scale (GCS) score and hematoma volume were used to assess severity. Poor prognosis was defined as a Glasgow Outcome Scale (GOS) score of 1– 3 at 90 days after ICH. Results: Plasma SIRT3 levels were markedly lower in patients than in controls (median, 10.19 versus 13.17 ng/mL; P< 0.001). Among all patients, plasma SIRT3 levels were independently correlated with hematoma volume (beta, − 0.098; 95% confidence interval, − 0.158--0.039; t , − 3.282; P=0.001) and GCS score (beta, 0.465; 95% confidence interval, 0.107– 0.823; t , 2.576; P=0.011). A total of 46 cases had a poor prognosis at post-stroke 90 days. The plasma levels of SIRT3 significantly decreased in patients with a poor prognosis, compared with those with a good prognosis (median, 6.1 versus 11.2 ng/mL; P< 0.001). Plasma SIRT3 was an independent predictor for 90-day poor prognosis of patients (odds ratio, 0.837; 95% confidence interval, 0.708– 0.990; P=0.038). Plasma SIRT3 levels distinguished the development of poor prognosis with area under receiver operating characteristic curve at 0.801 (95% confidence interval, 0.711– 0.872) and plasma SIRT3 levels ≤ 7.38 ng/mL predicted poor prognosis with 63.04% sensitivity and 93.22% specificity. Conclusion: Declined plasma SIRT3 levels are highly associated with hemorrhagic severity and poor 90-day outcome, thus suggesting that plasma SIRT3 may serve as a potential prognostic biomarker for ICH. Keywords: intracerebral hemorrhage, prognosis, severity, SIRT3, outcome Intracerebral hemorrhage (ICH) is a serious public health problem with high rates of death and disability, and it accounts for 10–20% of stroke worldwide. 1,2 Secondary brain injury induces perihematomal edema and therefore increases intracranial pressure, finally leading to a poor prognosis after ICH. 3,4 The initial hematoma induces glutamate release and then leads to oxidative stress and mitochondrial dysfunction. Mitochondrial dysfunction may contribute to the deficiency of adenosine triphosphate generation and then result in the failure of cellular pumps, which causes cytotoxic edema and neuronal apoptosis. 5–8 Thus, inhibiting oxidative stress may be an effective method in decreasing ICH injury. In addition, some biomarkers, which are related to inflammation, oxidative stress, neuronal apoptosis and brain edema, have been extensively studied with respect to outcome prediction and severity assessment. 9,10 Recently, several systematic reviews and clinical studies of multiple biomarkers have shown that those biochemical markers, eg, E-selectin, P-selectin, matrix metalloprotein-9, homocysteine and C-reactive protein, are strongly associated with clinical outcomes of ICH, but they have not been used in clinical work because of their low clinical predictive significance. 11 Thus, studies in search of new biomarkers are under way for aiding in ICH prognostic prediction. The sirtuins, as a family of highly conservative NAD + -dependent enzymes, participate in transcriptional silencing and regulation of mitochondrial functions. 12 As one of the known seven members of the sirtuin family, SIRT3 is distinguished by its main localization in mitochondria. 13–15 Of note, SIRT3 obviously attenuated doxorubicin-induced reactive oxygen species (ROS) output in H9c2 cardiomyocytes. 16 Int -Abstract Truncated-
psychiatry,clinical neurology